We are live on ! Find out more
VYGR icon

Voyager Therapeutics
VYGR

98 hedge funds and large institutions have $418M invested in Voyager Therapeutics in 2017 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 37 increasing their positions, 16 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 17

131% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 16

80% more capital invested

Capital invested by funds: $233M → $418M (+$185M)

46% more call options, than puts

Call options by funds: $1.84M | Put options by funds: $1.26M

38.03% more ownership

Funds ownership: 42.06% → 80.08% (+38%)

31% more funds holding

Funds holding: 75 → 98 (+23)

Holders
98
Holders Change
+23
Holders Change %
+30.67%
% of All Funds
2.22%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
40
Increased
37
Reduced
16
Closed
17
Calls
$1.84M
Puts
$1.26M
Net Calls
+$580K
Net Calls Change
-$3M

Top Buyers

Rank Fund Capital Flow
1
BB
BB Biotech
Switzerland
+$26.4M
2
BlackRock
BlackRock
New York
+$8.82M
3
FCM
Farallon Capital Management
California
+$8.35M
4
LCM
Laurion Capital Management
New York
+$7.94M
5
Axa
Axa
France
+$5.77M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$8.19M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.05M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$5.49M
4
BBA
Baker Bros. Advisors
New York
-$4.88M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP III
Massachusetts
$156M +$161M +9,391,176 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$54.6M -$7.05M -411,000 -11%
BB
3
BB Biotech
Switzerland
$25.6M +$26.4M +1,539,520 New
BlackRock
4
BlackRock
New York
$20.1M +$8.82M +514,345 +74%
CC
5
Casdin Capital
New York
$18.8M +$5.49M +320,000 +39%
Vanguard Group
6
Vanguard Group
Pennsylvania
$15.8M +$4.28M +249,803 +36%
EAM
7
Eventide Asset Management
Massachusetts
$11.7M +$2.43M +142,000 +25%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$10.9M -$5.49M -320,000 -33%
FCM
9
Farallon Capital Management
California
$10.9M +$8.35M +487,147 +291%
LCM
10
Laurion Capital Management
New York
$7.68M +$7.94M +462,905 New
Wells Fargo
11
Wells Fargo
California
$7.46M +$1.24M +72,335 +19%
Axa
12
Axa
France
$5.59M +$5.77M +336,807 New
Millennium Management
13
Millennium Management
New York
$4.58M +$4.73M +275,873 New
UBS AM
14
UBS AM
Illinois
$4.45M +$4.6M +268,155 New
AGA
15
Altrinsic Global Advisors
Connecticut
$4.4M +$1.71M +100,000 +61%
State Street
16
State Street
Massachusetts
$3.85M +$574K +33,502 +17%
TCP
17
Tourbillon Capital Partners
New York
$3.82M +$3.94M +230,000 New
Wellington Management Group
18
Wellington Management Group
Massachusetts
$3.23M -$85K -4,960 -2%
Northern Trust
19
Northern Trust
Illinois
$3.22M +$696K +40,606 +26%
PP
20
PDT Partners
New York
$2.9M +$1.91M +111,113 +176%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$2.87M +$536K +31,248 +22%
Morgan Stanley
22
Morgan Stanley
New York
$2.86M +$2.42M +141,144 +454%
Balyasny Asset Management
23
Balyasny Asset Management
Illinois
$2.72M +$2.81M +163,811 New
DCM
24
DAFNA Capital Management
California
$2.61M +$681K +39,741 +34%
DM
25
Deerfield Management
New York
$1.95M – – –
1
2 3 4 5

VYGR Hedge Fund Activity: Q4 2017 in Review

98 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2017, worth a combined $418M — up 80% from $233M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new VYGR positions and 17 closed out — a net gain of 23 holders — while 37 added to existing stakes and 16 trimmed.

The largest buyer was BB Biotech, opening a new position worth an estimated $26.4M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $8.19M sold.

  • 98 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2017, up from 75 in Q3 2017.
  • Funds reported $418M of Voyager Therapeutics stock for Q4 2017, up 80% quarter-over-quarter.
  • 40 funds opened new Voyager Therapeutics positions in Q4 2017 and 17 closed out, a net change of +23 holders.
  • The largest Voyager Therapeutics buyer in Q4 2017 was BB Biotech, an estimated $26.4M added.
  • The largest Voyager Therapeutics seller in Q4 2017 was PFM Health Sciences, an estimated $8.19M sold.

Based on aggregated 13F filings for Q4 2017.